Blood Test Could Predict Inflammatory Bowel Disease 10 Years Before Diagnosis

Blood Antibody Patterns Emerge a Decade Before Inflammatory Bowel Disease Diagnosis

Hidden changes in the human immune system can appear up to ten years before a patient receives an inflammatory bowel disease diagnosis, according to research presented at UEG Week 2026 in Barcelona and detailed by Science Daily.

Decoding Early Immune System Shifts

Inflammatory bowel disease encompasses long-term disorders such as Crohn’s disease and ulcerative colitis. These conditions cause persistent inflammation in the digestive tract when the immune system responds abnormally. While scientists have long suspected that these diseases develop quietly years before formal clinical detection, the exact immunological shifts during this prodromal phase remained poorly understood.

To trace these changes backward, researchers examined 2,000 blood serum samples from 500 participants. The cohort included 200 individuals who eventually developed Crohn’s disease, 200 who developed ulcerative colitis, and 100 healthy controls matched by age and sex. By analyzing samples drawn at diagnosis as well as two, four, and ten years prior, the team tracked a decade of immune activity.

The analysis mapped antibody reactions to roughly 357,000 antigens tied to bacteria, viruses, food, and human tissue, detecting 123,980 unique antibodies across all samples. A striking pattern emerged: participants who later developed either form of inflammatory bowel disease displayed significantly lower antibody diversity than healthy individuals. Their immune systems demonstrated a notably narrower range of responses.

Distinct Immunological Signatures for Crohn’s and Colitis

The research revealed diverging immune signals between the two primary disease subtypes. Individuals who went on to develop Crohn’s disease exhibited elevated antibody responses to herpesviruses and bacterial flagellin, a protein found in the tail-like structures bacteria use for movement. These heightened responses appeared most prominently in patients who later developed complicated Crohn’s disease or disease affecting the ileum, the final section of the small intestine. Conversely, antibody responses to encapsulated bacteria declined as diagnosis approached.

Participants who developed ulcerative colitis showed a different trajectory. Their antibody responses to herpesviruses and autoantigens—proteins from the body’s own tissues that mistakenly become immune targets—increased over time, while responses to encapsulated pathogens dropped.

Using machine learning models, the research team tested whether these antibody signatures could differentiate future patients from healthy controls. The predictive models distinguished future Crohn’s disease cases from healthy controls with an area under the curve of 0.90, while the corresponding value for ulcerative colitis stood at 0.84. Furthermore, the models distinguished patients destined for complicated Crohn’s disease from those with less complicated courses roughly a decade before diagnosis, yielding an AUC of 0.85.

Clinical Implications and Future Validation Steps

Lead author Dr. Arno Bourgonje noted that complicated Crohn’s disease at diagnosis links to a distinct antibody profile years prior to clinical symptoms, rather than simply stemming from post-diagnosis disease progression. Similarly, Marianne Radcliffe, chief executive of Crohn’s & Colitis UK, highlighted that uncovering changes occurring years before symptoms appear builds a clearer developmental understanding of these conditions.

Despite these promising statistical models, researchers stress that the approach is not yet ready for routine clinical screening. Additional work must establish whether antibody testing outperforms or adds meaningful value to existing genetic, clinical, and blood-based measurements. Any future screening tool must prove accurate, affordable, and reproducible in diverse, prospectively followed populations.

More on this story: Study: Upadacitinib Linked to Lower Treatment Failure in UC Patients

Photo: The Guardian

References

• Bourgonje, A.R. et al. Deciphering the prodrome of inflammatory bowel disease up to 10 years before disease onset by massively parallel serology. Presented at UEG Week 2026; 19 October 2026; Barcelona, Spain.
• Danne, C. et al. Neutrophils: From IBD to the gut microbiota. Nature Reviews Gastroenterology & Hepatology. 2024; 21:184-197.